Lower Tamiflu sales hit Chugai but oncology strong
This article was originally published in Scrip
A sharp drop in sales of flu drug Tamiflu (oseltamivir) dragged down revenues and profits at Roche's Japanese subsidiary Chugai in calendar 2010, although there was again strong underlying growth in the oncology sector.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.